Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Recruiting

Phase 2

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Sponsor:

Laboratoires Thea

Code:

NCT06627179

Conditions

Retinitis Pigmentosa (RP)

Usher Syndrome Type 2

Deaf Blind

Retinal Disease

Eye Diseases, Hereditary

Eligibility Criteria

Sex: All

Age: 8+

Healthy Volunteers: Not accepted

Interventions

Intravitreal Injection of Ultevursen

No intervention, will not receive any active study intervention

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-12. This information was provided to ClinicalTrials.gov by Laboratoires Thea on 2025-05-25.